Asensia Diabetes Care and Glooko said today they inked a global technology partnership deal through which Glooko’s Diabetes data management platform will be integrated with Ascensia’s Contour Next One and Contour Plus One blood glucose monitors.
The integration of the systems will allow direct access to blood glucose data through Glooko’s mobile application and clinic data upload products directly from the Contour Next One and Contour Plus One meters. Data will be communicated via bluetooth, with an automatic feed through the Contour Cloud, the companies said.
“Glooko’s Diabetes data management platform has become widely used for both personal and clinical diabetes data analytics and decision support. Glooko’s broad distribution into health systems will enable us to easily and seamlessly deliver highly accurate data from our Contour Next One and Contour Plus One blood glucose monitoring systems to clinicians right in their workflow. By linking our systems to Glooko’s Diabetes data management platform, we want to enable better understanding and analysis of diabetes data, and ultimately help to improve the lives of people with diabetes,” Ascensia Diabetes CEO Michael Kloss said in prepared remarks.
Health care workers will be able to access data from either of the Ascensia systems through Glooko’s Clinic Solution, the companies said. Ascencia’s Contour Next One recently won FDA 510(k) clearance and the company expects to launch the system in the US in early 2017.
The agreement will cover all markets where Glooko and Ascnesia’s systems are marketed, and is expected to be available in late 2017.
“The usability and accuracy of the Contour Next One and Contour Plus One blood glucose monitoring systems from Ascensia Diabetes Care is impressive and we are excited to bring this rich data into the Glooko platform to help both people with diabetes and their health care professionals manage this condition,” Glooko CEO Rick Altinger said in a press release.
The newly merged firms said their platforms operate in 4,000 diabetes clinics in 23 countries, covering more than 95% of diabetes devices used worldwide.
The companies recently raised $8 million in a new equity financing round to support accelerated integration and sales efforts. The round was led by venture capital firm Canaan Partners and joined by Social Capital, Samsung Ventures and Glooko founder Yogen Dalal.